Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Genetic Testing

Health Professionals:
Public Health Implications of UGT1A1 Genotyping and Use of Irinotecan Chemotherapy for Metastatic Colorectal Cancer


This page contains information that is not part of the EGAPP™ recommendation, but may be important for health professionals.

Public Health Implications

Colorectal cancer is the third leading cause of cancer in the United States with an estimated 142,000 new cases and more than 50,000 deaths estimated in 2010.[1]  Approximately 15% of cases involve distant metastasis and may be candidates for irinotecan therapy. Public health practitioners may choose to use this EGAPP™ recommendation information to support the following public health activities:

  • Assess current usage of genetic tests to determine the need for targeted educational campaigns aimed at informing providers and the public about EGAPP recommendations and limitations of UGT1A1 genotyping.
  • Disseminate these Web-based materials and the EGAPP™ recommendation to partners and other groups to increase awareness of these resources.

Top of Page




Top of Page


 

Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd.
    Atlanta, GA 30333 USA
    800-CDC-INFO (800-232-4636)
  • Additional information for Public Health Genomics is available on our contact page.
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #